ArticleEJNMMI research2025
Test-retest properties of [
Article in EJNMMI research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe metabotropic glutamate receptor 4 (mGlu4) has been proposed as a target for Parkinson’s disease to measure levodopa-induced dyskinesia. [11C]PXT012253 is a PET radioligand for mGlu4 (3.4 nM), previously characterized in non-human primates. We aimed to determine the optimal method for quantification, duration for acquisition, and test-retest reliability of the binding parameters for [11C]PXT012253 in healthy volunteers.
resultsSix subjects (4 females) completed. [11C]PXT012253 displayed high uptake and rapid wash-out. Unchanged [11C]PXT012253 at 20 min was 10–20%. VT in subcortical regions was higher than in cortical regions. 2TC provided better fits than 1TC. VT by Logan GA and MA1 analysis correlated with that of 2TC-CM. MA1 showed better identifiability and standard error than Logan. The test-retest metrics in pons, putamen and thalamus showed absolute variability of VT<7% and ICC > 0.93 using the 2TC, Logan and MA1 graphical analyses. Time stability analysis showed that VT values estimated using 63 min of imaging were within 10% of the values obtained with 93 min with all three models.
conclusion[11C]PXT012253 showed a high brain uptake, with rapid washout and metabolism. VT was reliably estimated using 2TC, Logan GA and MA1. The test-retest metrics showed high repeatability, indicating [11C]PXT012253 to be a suitable PET radioligand for mGlu4.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.